Survodutide – Medxy AI

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes: A Contemporary Review of Evidence and Clinical Implications

By MedXY 10/17/2026

Survodutide, a dual glucagon and GLP-1 receptor agonist, demonstrates significant weight loss and glycemic improvements in adults with obesity and type 2 diabetes, offering promise as a novel therapeutic agent with favorable efficacy and safety profiles.

Diabetes & Endocrinology Gastroenterology news

Disentangling Weight Loss-Dependent and Independent Effects of Survodutide on Liver Outcomes in MASH: Insights from a Phase 2 Mediation Analysis

By MedXY 08/04/2026

This mediation analysis of a phase 2 MASH trial reveals that survodutide improves liver inflammation and fibrosis predominantly through weight-independent mechanisms, highlighting a potential direct hepatic effect beyond weight reduction.